Licochalcone A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Licochalcone A 表现出有效的抗疟活性，并可能被开发成一种新的抗疟药物。

Licochalcone A exhibits potent antimalarial activity via and might be developed into a new antimalarial drug. Licochalcone A had anti-tumor activity in all cell lines tested and enhanced the effect of paclitaxel and vinblastine chemotherapy. Licochalcone A induced apoptosis in MCF-7 and HL-60 cell lines, as demonstrated by cleavage of PARP, the substrate of ICE-like proteases. Licochalcone A exhibits a strong antileishmanial activity ,that appropriate substituted chalcones might be a new class of antileishmanial drugs.(In Vitro):Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .

Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .

——

Licochalcone A | Licochalcone-A

Proteasome/Ubiquitin

Caspase

Caspase-3

Cancer

——

58749-22-7

338.4

C21H22O4

>98% (HPLC)

Soluble in DMSO, Chloroform

O=C(C1=CC=C(O)C=C1)/C=C/C2=CC(C(C)(C)C=C)=C(O)C=C2OC

(E)-3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one

(-20℃)

With Ice Pack

≥ 2 years